Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

被引：0

作者：

Vega-Ruiz, Arturo ^{[1
]}

O'Brien, Susan ^{[1
]}

Cortes, Jorge ^{[1
]}

Kebriaei, Partow ^{[2
]}

Thomas, Deborah ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Ravandi, Farhad ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 09期

关键词：

Philadelphia-positive acute lymphoblastic leukemia; imatinib mesylate; myelodysplastic syndrome;

D O I：

10.1016/j.leukres.2008.02.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1468 / 1471

页数：4

共 26 条

[11] Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with Imatinib (STI-571) [J].

Leis, JF ;

Stepan, DE ;

Curtin, PT ;

Ford, JM ;

Peng, B ;

Schubach, S ;

Druker, BJ ;

Maziarz, RT .

LEUKEMIA & LYMPHOMA, 2004, 45 (04) :695-698

[12] Therapy-related leukemia and myelodysplasia: susceptibility and incidence [J].

Leone, Giuseppe ;

Pagano, Livio ;

Ben-Yehuda, Dina ;

Voso, Maria Teresa .

HAEMATOLOGICA, 2007, 92 (10) :1389-1398

[13] Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib [J].

Meeus, P ;

Demuynck, H ;

Martiat, P ;

Michaux, L ;

Wouters, E ;

Hagemeijer, A .

LEUKEMIA, 2003, 17 (02) :465-467

[14] What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph+ ALL? [J].

Mele, Giuseppe ;

Pinna, Salvatore ;

Melpignano, Angela ;

Romano, Antonio ;

Brocca, Maurizio Claudio ;

Coppi, Maria Rosaria ;

Quarta, Giovanni .

LEUKEMIA RESEARCH, 2007, 31 (10) :1445-1447

[15] Myelodysplastic features developing in Philadelphia-negative cells during imatinib mesylate therapy for CML:: report of a new case [J].

Mozziconacci, MJ ;

Caillères, S ;

Maurice, C ;

Vey, N ;

Sainty, D ;

Blaise, D ;

Lafage-Pochitaloff, M .

LEUKEMIA, 2003, 17 (09) :1901-1902

[16] Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myelold leukemia:: Two cases with a different outcome [J].

Navarro, Jose-Torns ;

Feliu, Evarist ;

Grau, Javier ;

Espinet, Blanca ;

Colorner, Dolors ;

Ribera, Josep-Maria ;

Oriol, Albert ;

Granada, Isabel ;

Junc, Jordi ;

Milla, Fuensanta .

AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (09) :849-851

[17] Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate [J].

O'Dwyer, ME ;

Gatter, KM ;

Loriaux, M ;

Druker, BJ ;

Olson, SB ;

Magenis, RE ;

Lawce, H ;

Mauro, MJ ;

Maziarz, RT ;

Braziel, RM .

LEUKEMIA, 2003, 17 (03) :481-487

[18]

Pfeifer H, 2003, CLIN CANCER RES, V9, P4674

[19] Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia [J].

Piccaluga, Pier Paolo ;

Paolini, Stefania ;

Martinelli, Giovanni .

CANCER, 2007, 110 (06) :1178-1186

[20] Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia [J].

Relling, MV ;

Yanishevski, Y ;

Nemec, J ;

Evans, WE ;

Boyett, JM ;

Behm, FG ;

Pui, CH .

LEUKEMIA, 1998, 12 (03) :346-352

← 1 2 3 →